Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma

F. Landoni, A. Maneo, A. Colombo, G. Cormio, F. Placa, S. Nava, R. Rossi, C. Mangioni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite innovative techniques in radiotherapy delivery no significant improvement in survival rates for cervical carcinoma has been achieved during the last few decades. Concurrent chemoradiation (CR) is one of the several avenues being explored to improve these results. Forty-seven women with locally advanced (IB2-IVA) squamous cell carcinoma of the uterine cervix were treated with CR, comprising a combination of external and intracavitary radiation along with three cycles of 5-FU and carboplatin. Treatment was well tolerated with 81% of the patients completing the CR protocol as planned. Acute toxicity was severe but manageable: 16 patients (34%) experienced grade 3-4 acute toxicity. Late morbidity occurred in 15% of the patients. Overall response rate was 88%. At a median follow-up time of 19 months (range 12-59) 62% of the patients are alive without disease and 18% are dead of disease. Actuarial two-year survival rate for the whole group of patients is 64%. Concomitant carboplatin/5-FU and radiotherapy is a safe and tolerable mean of treatment for locally advanced cervical cancer. The true advantage for survival, however, can be demonstrated only after completion of randomized trials comparing CR with conventional radiation therapy.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume7
Issue number6
Publication statusPublished - 1997

Fingerprint

Carboplatin
Fluorouracil
Radiotherapy
Carcinoma
Survival Rate
Cervix Uteri
Uterine Cervical Neoplasms
Squamous Cell Carcinoma
Radiation
Morbidity
Survival
Therapeutics

Keywords

  • 5-Fluorouracil
  • Carboplatin
  • Cervical carcinoma
  • Chemoradiation

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynaecology
  • Oncology

Cite this

Landoni, F., Maneo, A., Colombo, A., Cormio, G., Placa, F., Nava, S., ... Mangioni, C. (1997). Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma. International Journal of Gynecological Cancer, 7(6), 471-476.

Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma. / Landoni, F.; Maneo, A.; Colombo, A.; Cormio, G.; Placa, F.; Nava, S.; Rossi, R.; Mangioni, C.

In: International Journal of Gynecological Cancer, Vol. 7, No. 6, 1997, p. 471-476.

Research output: Contribution to journalArticle

Landoni, F, Maneo, A, Colombo, A, Cormio, G, Placa, F, Nava, S, Rossi, R & Mangioni, C 1997, 'Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma', International Journal of Gynecological Cancer, vol. 7, no. 6, pp. 471-476.
Landoni F, Maneo A, Colombo A, Cormio G, Placa F, Nava S et al. Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma. International Journal of Gynecological Cancer. 1997;7(6):471-476.
Landoni, F. ; Maneo, A. ; Colombo, A. ; Cormio, G. ; Placa, F. ; Nava, S. ; Rossi, R. ; Mangioni, C. / Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma. In: International Journal of Gynecological Cancer. 1997 ; Vol. 7, No. 6. pp. 471-476.
@article{0f4266d7d59d4ff59163c76fd083e5aa,
title = "Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma",
abstract = "Despite innovative techniques in radiotherapy delivery no significant improvement in survival rates for cervical carcinoma has been achieved during the last few decades. Concurrent chemoradiation (CR) is one of the several avenues being explored to improve these results. Forty-seven women with locally advanced (IB2-IVA) squamous cell carcinoma of the uterine cervix were treated with CR, comprising a combination of external and intracavitary radiation along with three cycles of 5-FU and carboplatin. Treatment was well tolerated with 81{\%} of the patients completing the CR protocol as planned. Acute toxicity was severe but manageable: 16 patients (34{\%}) experienced grade 3-4 acute toxicity. Late morbidity occurred in 15{\%} of the patients. Overall response rate was 88{\%}. At a median follow-up time of 19 months (range 12-59) 62{\%} of the patients are alive without disease and 18{\%} are dead of disease. Actuarial two-year survival rate for the whole group of patients is 64{\%}. Concomitant carboplatin/5-FU and radiotherapy is a safe and tolerable mean of treatment for locally advanced cervical cancer. The true advantage for survival, however, can be demonstrated only after completion of randomized trials comparing CR with conventional radiation therapy.",
keywords = "5-Fluorouracil, Carboplatin, Cervical carcinoma, Chemoradiation",
author = "F. Landoni and A. Maneo and A. Colombo and G. Cormio and F. Placa and S. Nava and R. Rossi and C. Mangioni",
year = "1997",
language = "English",
volume = "7",
pages = "471--476",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma

AU - Landoni, F.

AU - Maneo, A.

AU - Colombo, A.

AU - Cormio, G.

AU - Placa, F.

AU - Nava, S.

AU - Rossi, R.

AU - Mangioni, C.

PY - 1997

Y1 - 1997

N2 - Despite innovative techniques in radiotherapy delivery no significant improvement in survival rates for cervical carcinoma has been achieved during the last few decades. Concurrent chemoradiation (CR) is one of the several avenues being explored to improve these results. Forty-seven women with locally advanced (IB2-IVA) squamous cell carcinoma of the uterine cervix were treated with CR, comprising a combination of external and intracavitary radiation along with three cycles of 5-FU and carboplatin. Treatment was well tolerated with 81% of the patients completing the CR protocol as planned. Acute toxicity was severe but manageable: 16 patients (34%) experienced grade 3-4 acute toxicity. Late morbidity occurred in 15% of the patients. Overall response rate was 88%. At a median follow-up time of 19 months (range 12-59) 62% of the patients are alive without disease and 18% are dead of disease. Actuarial two-year survival rate for the whole group of patients is 64%. Concomitant carboplatin/5-FU and radiotherapy is a safe and tolerable mean of treatment for locally advanced cervical cancer. The true advantage for survival, however, can be demonstrated only after completion of randomized trials comparing CR with conventional radiation therapy.

AB - Despite innovative techniques in radiotherapy delivery no significant improvement in survival rates for cervical carcinoma has been achieved during the last few decades. Concurrent chemoradiation (CR) is one of the several avenues being explored to improve these results. Forty-seven women with locally advanced (IB2-IVA) squamous cell carcinoma of the uterine cervix were treated with CR, comprising a combination of external and intracavitary radiation along with three cycles of 5-FU and carboplatin. Treatment was well tolerated with 81% of the patients completing the CR protocol as planned. Acute toxicity was severe but manageable: 16 patients (34%) experienced grade 3-4 acute toxicity. Late morbidity occurred in 15% of the patients. Overall response rate was 88%. At a median follow-up time of 19 months (range 12-59) 62% of the patients are alive without disease and 18% are dead of disease. Actuarial two-year survival rate for the whole group of patients is 64%. Concomitant carboplatin/5-FU and radiotherapy is a safe and tolerable mean of treatment for locally advanced cervical cancer. The true advantage for survival, however, can be demonstrated only after completion of randomized trials comparing CR with conventional radiation therapy.

KW - 5-Fluorouracil

KW - Carboplatin

KW - Cervical carcinoma

KW - Chemoradiation

UR - http://www.scopus.com/inward/record.url?scp=0031434976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031434976&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031434976

VL - 7

SP - 471

EP - 476

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -